A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

Anything that helps Americans lose weight, reduces treatment barriers and makes care more affordable should be welcomed. But let's not fool ourselves.

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...

At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...

Virginia university leads trial testing ARD-201, an oral drug to maintain weight loss after stopping GLP-1 treatments like ...

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight ...

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions ...

Research has shown that people who stop taking GLP-1 drugs, such as Ozempic and Wegovy, typically experience weight regain ...

Aurora IV and Wellness, a Cullman-based clinic, has been permanently closed following a state investigation that revealed the ...

Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods. Weight-loss experts spoke with Fox News Digital about ...

A 2026 Investigation Into the Mitochondria Theory, Real Results, Side Effects, and the Truth Behind the Reviews. NEW YORK, NY / ACCESS Newswire / January 9, 2026 / By early 2026, Mitolyn reviews are ...

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. This rate of weight regain is significantly faster than ...